Metrics raised 1
- FY27 pen delivery guidance raised to exceed 36 million units (from 36 million units)
Event Participants
Executives
2 Amit Sanghvi, Sanjay Shah
Analysts
10 Akhil Parekh, Aman Vij, Harshh Shah, Ishika Garg, Nirali Gopani, Ritesh Shah, Rupesh Tatiya, Sanjay Kumar, Shaleen Kumar, Vinil Shah
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Revenue | ₹281 crores | +14% YoY from ₹247 crores; healthcare growth offset consumer softness |
| Healthcare revenue | ₹142 crores | +85% YoY; ~51% of consolidated revenue, now largest segment; led by pen injectors for GLP1/insulin |
| Consumer revenue | ₹116 crores | -24% YoY; softer home furnishings demand across Europe and US |
| Industrial revenue | ₹23 crores | +25% YoY; new customer additions, consumer electronics and semiconductor trays |
| EBITDA | ₹83 crores | +18% YoY; margin 29.7%, +120 bps YoY |
| PAT | ₹48 crores | +17% YoY; margin 17.1%, +40 bps YoY |
| Machine utilization | 50.2% | vs 48.7% in Q1FY26; gradual improvement in capacity utilization |
| Exports share | 58% | vs 76% Q1FY26; mix shift due to healthcare supplied to Indian pharma partners for global markets |
| Device volumes | ~9 million units | Q1 delivery devices; 50-60% GLP1, balance insulin plus other molecules |
| Pen capacity | ~75 million pens/annum | Post addition of 25 million capacity line expected operational by end-September |
Geographic & Segment Commentary
Healthcare: Segment revenue grew 85% YoY to ₹142 crores, representing 51% of consolidated revenue. Growth led by pen injector platform for GLP1 and chronic therapies; orders received for injector pen supplies following regulatory approvals for semaglutide in Canada and Brazil. Six of eight device platforms are now fully commercial and sold across global markets; two new platform projects signed during the quarter.
Consumer: Revenue declined 24% YoY to ₹116 crores (~41% of total) due to softer home furnishings demand across Europe and US, the largest export markets. Management guided the segment to remain flat YoY in FY27. Secured a global project from an FMCG customer and new business in LED lighting to strengthen the future pipeline.
Industrial: Revenue grew 25% YoY to ₹23 crores, supported by new customer additions and opportunities across engineering applications including consumer electronics. Received business confirmations for new projects from appliance and automotive customers; onboarded a new customer with orders covering five consumer electronic components.
Company-Specific & Strategic Commentary
Pen Capacity Expansion: Additional 25 million pen capacity expected operational by end-September, taking total installed pen injector capacity to ~75 million pens per annum. Existing line efficiency improved ~9%; additional equipment expected to drive another ~30% jump before Q2 end.
Healthcare Innovation Pipeline: Reusable auto injectors to be showcased at CPHI Milan, targeting launch by end of year; emergency-use auto injector in development (~18 months in) requiring 99.999% device activation reliability; on-body injectors (3-15 mL) under development for oncology/biosimilars. No plans to enter pharma consumables or inhalers.
Global BD Expansion: Dedicated heads of business development appointed for Europe (HEC Paris MBA, drug delivery experience) and North America (background from West, Philips, Medline, Steven Otto, Hasselmeyer, Shiley); management confident of securing innovator pharma partnership within 4-6 quarters.
Consumer Electronics & Semiconductors: Commercial supply to consumer electronics customer started; five new components awarded for supply before FY27 end. Semiconductor trays commercial supply expected Q4 FY27 with ~₹5 crores capex; consumer electronics plant (south India) land secured, capex of ₹80-100 crores planned; $10 million revenue target within 24-30 months (not formal guidance).
Abu Dhabi Facility: Commercial production targeted by end-FY28; 50-55% of capacity commitments/indications secured; capacity positioned for European market opening in 2028 and global markets in 2030-31.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| Pen deliveries | 36 million units FY27 (likely exceeded) | Management expects to go beyond 36 million assuming demand holds and new line ramps as planned; supply chain issues at partner level are a variable |
| Gross margin | Normalize by Q3 FY27 | Geopolitics-driven polymer/freight cost increases and premium freight (airlift) caused compression; pass-through lags of 1-2 months |
| Consumer segment | Flat YoY in FY27 | No growth expected; EU/US home furnishings demand softness persists |
| Semiconductor revenue | Q4 FY27 start | Initial supplies from existing facility with ~₹5 crores investment |
| UK subsidiary | Growth over next three quarters | Q1 revenue dip is milestone-timing related; invoices raised only on customer confirmation |
| Innovator partnership | Within 4-6 quarters | Hires of Europe/North America BD heads expected to accelerate discussions |
Risks & Constraints
| Risk | Context |
|---|---|
| Geopolitical & supply chain disruption | West Asia situation causing polymer price volatility, container shortages and elevated freight; management mitigated via calibrated pricing and pass-through mechanisms; gross margin impacted in Q1 with normalization expected by Q3 |
| Consumer demand softness | Home furnishings demand weak in Europe and US; segment declined 24% YoY and is guided flat for FY27; recovery dependent on macro recovery in key export markets |
| Line ramp-up execution | New pen line ran at below-optimal efficiency; ~30% production uplift pending equipment installation before Q2 end; second line strategy changed to supplier-side ramp-up (80% cost efficiency at FAT) to de-risk |
| Competition from Chinese manufacturers | Chinese GLP1 devices priced $1.50-1.70 (vs Shaily's >$2); products described as 20-year-old copycat technology with patent infringement concerns; management not overly concerned near term |
| Partner-specific issues | One pharma customer (not officially named, media refers to Dr. Reddy's) faces impurity-related regulatory issues in Canada/Brazil; management states device supply increases to fill gaps and remains confident in guidance |
Q&A Highlights
Pen volumes, mix and guidance
- Question: How many pens shipped in Q1, and what is the GLP1 versus insulin mix? (Shaleen Kumar, UBS)
- Answer: ~9 million delivery devices shipped; 50-60% GLP1, remainder insulin and other molecules (Amit Sanghvi). Existing line efficiency improved 9%; another 30% jump expected once pending equipment is installed before quarter end (Amit Sanghvi). On FY27 guidance: "we should be able to go beyond 36 million" assuming demand holds (Amit Sanghvi).
Line ramp-up strategy and new line de-risking
- Question: Will the second pen line face similar ramp-up challenges as the first? (Shaleen Kumar, UBS)
- Answer: Strategy changed—supplier will ramp to 80% cost efficiency before FAT and shipment; no R&D at Shaily's site; once line arrives, similar efficiencies achievable within a month or two (Amit Sanghvi).
Gross margin compression and pricing model
- Question: Why did gross margin decline sequentially despite a richer healthcare mix? (Ritesh Shah, Investec)
- Answer: Post-March war-related commodity price increase, freight spike, and premium freight (airlifting material) drove compression; pass-through with customers delayed (May-June, some July); normalization expected by Q3 (Sanjay Shah, Amit Sanghvi). Business is not cost-plus—pricing is IP-led with annual reviews based on inflation, polymers, contract longevity and commitment (Amit Sanghvi).
Competition and pricing on Chinese GLP1 devices
- Question: How should we view pricing given Chinese players entering the supply curve? (Ritesh Shah, Investec)
- Answer: Chinese products priced $1.50-1.70 are copycat, 20-year-old technology, some infringing patents; Shaily's devices priced above $2; competition not a major near-term concern; strategy being developed (Amit Sanghvi).
Dr. Reddy's order and guidance confidence
- Question: With partner impurity issues in Canada/Brazil, how comfortable are you with 36 million pen guidance? (Ritesh Shah, Investec)
- Answer: Company does not name customers; device supply increases to fill partner gaps; approvals across multiple markets remain; confident in guidance (Amit Sanghvi, Sanjay Shah).
Abu Dhabi capacity commitments
- Question: What's the status of conversations on Abu Dhabi capacity? (Harshh Shah, JM Financial)
- Answer: 50-55% of capacity has commitments/indications; plant targeted for commercial sales by end-FY28; capacity primarily for Europe opening in 2028 and global markets in 2030-31 (Amit Sanghvi).
Consumer electronics scale potential
- Question: What scale can consumer electronics reach in 2-3 years? (Harshh Shah, JM Financial)
- Answer: ~$10 million revenue within 24-30 months is the current projection, not formal guidance; portfolio and customer base being built (Amit Sanghvi, Sanjay Shah).
Healthcare innovation pipeline
- Question: What stage are emergency-use, reusable and on-body injectors at, and what's the moat? (Ritesh Shah, Investec; Nirali Gopani, Unique PMS)
- Answer: Reusable auto injector to be showcased at CPHI Milan with launch by year-end; emergency-use device (~18 months in) requires statistically proven 99.999% reliability and we'll close it by end-2027; on-body injector in development for oncology/biosimilars with 3-15 mL range (Amit Sanghvi). Emergency-use device pricing $6-10/unit, on-body $25-35/unit; high value, high margin, low volume therapies (Amit Sanghvi).
Business development hires for Europe and North America
- Question: Any details on the new BD heads and their roles? (Akhil Parekh, 360 ONE Capital)
- Answer: European head—HEC Paris MBA, drug delivery experience; US head—from competitors (West, Philips, Medline, Steven Otto, Hasselmeyer, Shiley); both end-to-end roles covering technical discussions, scoping and development (Amit Sanghvi).
Semiconductor trays market opportunity
- Question: What's the right-to-win and market size for semiconductor trays? (Rupesh Tatiya, Long Equity Partners)
- Answer: Highly specialized trays with critical dimensional tolerances and specialized conductive plastics; fewer than a dozen global players; consumable product with demand in millions as India's semiconductor ecosystem develops; initial capex ~₹5 crores (Sanjay Shah).
Talent retention and ESOPs
- Question: How are you retaining employees given industry competition? (Ritesh Shah, Investec)
- Answer: Strong industry reputation, competitive pay, heavy investment in training; ESOPs exist with more employees becoming eligible in coming years; hires of BD heads reflect ability to attract senior talent (Amit Sanghvi).
Key Takeaway
Healthcare became Shaily's largest segment in Q1 FY27, with revenue of ₹142 crores (+85% YoY) at 51% of consolidated revenue of ₹281 crores (+14% YoY), driven by ~9 million pen injector deliveries skewed 50-60% toward GLP1 therapies. EBITDA grew 18% to ₹83 crores with margin up 120 bps to 29.7%, though gross margin compressed on polymer and freight headwinds expected to normalize by Q3. Management maintained FY27 pen guidance of 36 million units and indicated likely outperformance as the 25-million capacity line comes online and the existing line gains planned efficiency. Strategically, the company is scaling consumer electronics (five new components, $10 million revenue target in 24-30 months), semiconductor trays (Q4 start), and next-generation devices—reusable, emergency-use and on-body injectors—while targeting innovator partnerships within 4-6 quarters. Key watch points: EU/US home furnishings demand, line ramp-up execution, partner regulatory issues in Canada/Brazil, and Abu Dhabi plant commercialization by end-FY28.